
IL1RAP, a therapeutic target for oncologic treatment
Date of publication : 31/07/2020IL1-RAP, has been identified as a marker of interest in the context of CML treatments, activating NK cells and blocking tumour growth at the same time. Diaclone and Inserm teams have been able to develop a CAR-T therapy to specifically target this biomarker, which has demonstrated great promise during preclinical studies.
Read more on Linked In
Discover Diaclone's new IL1RAP clones:
Anti-Human IL1RAP B-L43 Azide Free | |||
Anti-Human IL1RAP B-R58 Azide Free | |||
Anti-Human IL1RAP B-L43 Unconjugated | |||
Anti-Human IL1RAP B-R58 Unconjugated |
Another immuno-oncology target you would like to discuss?
Not fully aware of our complete immuno-oncology portfolio